Comparative Pharmacology
Head-to-head clinical analysis: OVIDE versus XEGLYZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVIDE versus XEGLYZE.
OVIDE vs XEGLYZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OVIDE (malathion) is an organophosphate insecticide that irreversibly inhibits acetylcholinesterase, leading to accumulation of acetylcholine at synapses, resulting in paralysis and death of lice. It also has pediculicidal and ovicidal activity.
Glucagon-like peptide-1 (GLP-1) receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
Apply OVIDE (malathion 0.5% lotion) topically to dry hair and scalp, leave for 8-12 hours, then rinse thoroughly. Repeat in 7-9 days if live lice persist.
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 8–10 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life is 12 hours, supporting once-daily dosing in patients with normal renal function.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for <5%.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing about 30%.
Category C
Category C
Pediculicide
Pediculicide